Cancer detection in 18F-FDG-PET/CT vs CT in patients with nonspecific signs and symptoms of cancer.
Imaging with 18F-FDG-PET/CT compared to CT for detecting cancer in patients with nonspecific signs and symptoms of cancer (NSSC) provides a higher diagnostic specificity and accuracy than does CT alone, according to a study published in The Journal of Nuclear Medicine.
Researchers from Denmark conducted a randomized prospective trial of patients with serious NSSC symptoms to determine if 18F-FDG-PET/CT was superior to CT as initial imaging modality in this patient group.
Two-hundred patients participated in the trial, randomized 1:1 to whole body 18F-FDG-PET/CT or CT of the thorax and abdomen as imaging modality. A tentative diagnosis was established after first line imaging. The final referral diagnosis was adjudicated by the physician, when sufficient data was available. Results were available for 197 patients.
Diagnosis following examination included:
• 39 patients (20%) were diagnosed with cancer
• 10 (5%) with an infection
• 15 (8%) with an autoimmune disease
• 76 (39%) with other diseases
• 57 patients (28%) no specific disease found
“Compared to CT scans, 18F-FDG-PET/CT had a higher specificity (96% versus 85%) and a higher accuracy (94% versus 82%),” the authors wrote. “However, there were no statistically significant differences in sensitivity (83% versus 70%) or negative predictive values (96% versus 92%).”
The researchers found no difference could be shown in days to final referral diagnosis in the randomization group (7.2 days compared with 7.6 days), but for the subgroups where the imaging modality showed suspicion of malignancy, there was a significant delay to final diagnosis in the CT group compared to the 18F-FDG-PET/CT group (11.6 compared with 5.7 days).
The researchers concluded that there was a higher diagnostic specificity and accuracy of 18F-FDG-PET/CT compared to CT for detecting cancer in patients with NSSC. 18F-FDG-PET/CT should therefore be considered as first line imaging in this group of patients.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.